Targeting the androgen receptor in hormone-refractory prostate cancer--new concepts

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The androgen receptor (AR) is crucial in both early and advanced prostate cancer.
• Therapy resistance in advanced prostate cancer often involves AR signaling.
• Novel therapeutic strategies targeting AR are needed for better disease control.

Purpose of the Study:

• To review recent therapeutic strategies targeting AR function in prostate cancer.
• To critically evaluate the clinical usefulness of these novel approaches.
• To explore methods for controlling disease progression in therapy-resistant prostate cancer.

Main Methods:

• Review of current literature on AR-targeting therapies.
• Categorization of strategies into direct AR inhibition and indirect AR signaling inactivation.
• Analysis of novel approaches including anti-androgens, AR modulators, antisense technology, and HSP degradation.

Main Results:

• Multiple direct AR inhibition strategies exist, including anti-androgens, selective modulators, and neutralizing antibodies.
• Antisense technology offers a unique approach to prevent AR expression transcriptionally.
• Indirect inactivation methods involve targeting heat-shock proteins and growth factor signaling pathways.

Conclusions:

• Targeting AR function is a key strategy for managing prostate cancer, especially in resistant forms.
• Various direct and indirect methods are under investigation with potential clinical utility.
• Further research is needed to optimize these novel AR-targeting therapies for improved patient outcomes.